Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...
LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock ...
StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a report released on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. MediciNova ...
MediciNova (MNOV) was notified by Sanofi (SNY) that the Sanofi/Novartis (NVS) litigation was settled. Accordingly, MediciNova is entitled to ...
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company ...
MediciNova, Inc. (NASDAQ:MNOV – Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday .The stock has a 200-day moving average of $1.50 and traded as high ...
Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is possibly considering an offer for the company. Avi ...
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...
LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback